Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel
NASDAQ:RLYB

Rallybio Q3 2025 Earnings Results & Report

Rallybio logo
$16.28 -0.49 (-2.92%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$16.33 +0.05 (+0.31%)
As of 10/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rallybio beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$1.12 versus the -$2.00 consensus estimate, while revenue of $0.21 million topped the $0.07 million estimate by $0.15 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Rallybio EPS Results

Actual EPS
-$1.12
Consensus EPS
-$2.00
Beat/Miss
Beat by +$0.88
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Rallybio Revenue Results

Actual Revenue
$0.21 million
Expected Revenue
$0.07 million
Beat/Miss
Beat by +$145.00 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Rallybio's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Powered by Quartr

Earnings Documents

Rallybio's Q3 2025 Earnings ReleaseEarnings Release
(8-K)
Rallybio's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

Rallybio Q3 2025 Earnings FAQ

Rallybio (NASDAQ:RLYB) reported earnings of -$1.12 per share for Q3 2025, beating the consensus estimate of -$2.00. The report was announced on Thursday, November 6, 2025.

Rallybio reported revenue of $0.21 million for Q3 2025, against a consensus estimate of $0.07 million.

Rallybio's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Rallybio on the company's earnings history page.

Rallybio Earnings Headlines

Head to Head Analysis: Alector (NASDAQ:ALEC) & Rallybio (NASDAQ:RLYB)
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109788
Rallybio CFO Transition Amid Pending Avenzo Therapeutics Merger
September 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/rallybio-cfo-transition-amid-pending-avenzo-therapeutics-merger?utm_source=marketbeat.com&utm_medium=referral
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
 |  Profits Run (Ad)
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
June 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260602266487/en/rallybio-investor-alert-kahn-swick-foti-llc-investigates-merger-of-rallybio-corporation---rlyb/
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own?
June 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/rlyb-stock-hits-2-highs-162629816.html
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
June 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260601190294/en/RLYB-Stock-Alert-Halper-Sadeh-LLC-is-Investigating-Whether-Rallybio-Corporation-is-Obtaining-a-Fair-Price-for-its-Shareholders/
See More Rallybio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Rallybio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rallybio and other key companies, straight to your email.

About Rallybio

Rallybio (NASDAQ:RLYB) is a clinical-stage biotechnology company focused on developing medicines for rare diseases and conditions with significant unmet medical needs. The company’s research and development efforts are directed toward therapies that address serious disorders in areas such as maternal-fetal health, hematology and immunology.

Rallybio’s lead program, RLYB212, is designed to prevent hemolytic disease of the fetus and newborn caused by maternal alloimmunization against the Kell antigen. The company has also developed investigational therapies that target the complement system, an immune pathway involved in a range of rare and severe diseases.

Founded in 2018, Rallybio is headquartered in New Haven, Connecticut. Its programs are being developed through clinical research intended to support potential future treatments in the United States and other markets, subject to regulatory approval. The company’s management and development teams include biotechnology and pharmaceutical industry professionals with experience in drug discovery, clinical development and commercialization.

View Rallybio Profile
Earnings Tools